MarketLens
Sign Up

Has ADC Therapeutics' ZYNLONTA Delivered on its Phase 3 Promise

4 months ago
SHARE THIS ON:

Has ADC Therapeutics' ZYNLONTA Delivered on its Phase 3 Promise

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•6 days ago

Genmab: Epkinly Shines In Phase 3 DLBCL Trial

Genmab reported topline Phase 3 results for Epkinly in frontline DLBCL, showing a 51% reduction in risk of progression or death. The efficacy exceeds Roche's Polivy in similar settings, potentially po...
Stock News•2 months ago

ADC Therapeutics Q2 Earnings Call Highlights

ADC Therapeutics' ZYNLONTA generated $18.6M in Q2 2026 net product revenue, up from $18.1M a year earlier, as executives said commercial performance stayed broadly consistent with recent quarters.
Stock News•3 months ago

Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?

BMY filed for FDA approval of mezigdomide in relapsed/refractory multiple myeloma, advancing its CELMoD protein degrader pipeline.

Breaking News

View All →

Top Headlines

View More →
Stock News•1 hour ago

Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

Stock News•1 hour ago

Why the Market Dipped But Microsoft (MSFT) Gained Today

Stock News•1 hour ago

Nvidia (NVDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Stock News•1 hour ago

Tesla (TSLA) Declines More Than Market: Some Information for Investors

Stock News•1 hour ago

Amazon Will Be The Final Winner Of The AI Race With Anthropic's Help